Saturday 17 October 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.03
0.53
−2.71%
Follow VRDN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
27.86 | 28.19 | 37.25 | 24.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(18.82) | (16.71) | (111.10) | (20.86) | |
P/B ratio |
3.51 | 3.97 | 4.47 | 5.62 | |
Price to Tangible BV |
3.58 | 3.97 | 4.47 | 5.62 | |
EV/Sales |
17.59 | 18.27 | 25.73 | 18.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.75) | (4.27) | (6.59) | (4.00) | |
EV/FCF |
(3.73) | (4.27) | (6.58) | (3.99) | |
Quick Ratio |
16.56 | 14.71 | 12.37 | 9.68 | |
Current Ratio |
16.95 | 15.15 | 12.65 | 11.28 | |
Net Debt/EBITDA |
5.79 | 6.04 | 6.63 | 11.45 | |
Debt/Assets |
22.07% | 6.39% | 5.55% | 3.62% | |
Debt/Equity |
0.37 | 0.08 | 0.07 | 0.04 | |
Asset Turnover |
0.08 | 0.10 | 0.09 | 0.10 | |
Operating CF/Net income |
0.83 | 1.14 | 0.20 | 2.45 | |
Capex/Depreciation |
0.98 | 0.01 | 0.15 | 0.12 | |
Interest Coverage |
(15.20) | (33.56) | (36.93) | (71.45) | |
Research and Development Expense of Revenue |
25,203.17% | 55,057.45% | 67,581.06% | 122.23% | |
Selling, General and Administrative Expense of Revenue |
19,357.39% | 27,431.91% | 25,510.61% | 34.47% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5,980.28% | 9,496.45% | 9,082.58% | 15.94% | |
Graham Net Nets |
0.33 | 0.32 | 0.27 | 0.28 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.35%) | (16.97%) | (10.57%) | (14.92%) | |
Free Cash Flow Yield |
(16.91%) | (15.20%) | (10.49%) | (18.49%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.86 | |
Operating CF per Share |
(0.98) | (1.17) | (0.28) | (1.03) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.99) | (1.17) | (0.28) | (1.04) | |
Cash per Share |
9.10 | 7.46 | 10.31 | 6.00 | |
Shareholders Equity per Share |
6.14 | 6.22 | 8.52 | 6.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.14 | 6.22 | 8.52 | 6.15 | |
Free Cash Flow |
(106.63) | (119.68) | (23.99) | (84.74) | |
Working Capital |
1,017.48 | 732.94 | 823.54 | 521.22 | |
Capital Expenditures |
(1.31) | (0.02) | (0.24) | (0.13) | |
Net Current Asset Value |
646.13 | 631.74 | 716.98 | 497.75 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
4.60 | 0.16 | 1.82 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
37.55 | — | — | — | |
Average Payables |
8.59 | 8.60 | 5.41 | 8.20 | |
Average Assets |
839.78 | 725.00 | 820.91 | 674.52 | |
Average Common Equity |
445.18 | 459.77 | 536.43 | 416.35 |
Columns are period end dates